Department of Anesthesiology, Academic Medical Center, University of Amsterdam, the Netherlands.
Reg Anesth Pain Med. 2012 Nov-Dec;37(6):601-6. doi: 10.1097/AAP.0b013e3182664afb.
Application of local anesthetics may lead to nerve damage. Increasing evidence suggests that risk of neurotoxicity is higher in patients with diabetic peripheral neuropathy. In addition, block duration may be prolonged in neuropathy. We sought to investigate neurotoxicity in vitro and block duration in vivo in a genetic animal model of diabetes mellitus type 2.
In the first experiments, neurons harvested from control Zucker diabetic fatty (ZDF) rats were exposed to acute (24 hours) or chronic (72 hours) hyperglycemia, followed by incubation with lidocaine 40 mM (approximately 1%). In a second experiment, neurons harvested from control ZDF rats, or diabetic ZDF rats, were incubated with lidocaine, with or without SB203580, an inhibitor of the p38 mitogen-activated protein kinase. Finally, we performed sciatic nerve block (lidocaine 2%, 0.2 mL) in control or diabetic ZDF rats and measured motor and nociceptive block duration.
In vitro, neither acute nor chronic hyperglycemia altered neurotoxic properties of lidocaine. In vitro, incubation of neurons with lidocaine resulted in a slightly decreased survival ratio when neurons were harvested from diabetic (57% ± 19%) as compared with control (64% ± 9%) rats. The addition of SB203580 partly reversed this enhanced neurotoxic effect and raised survival to 71% ± 12% in diabetic neurons and 66% ± 9% in control rats, respectively. In vivo, even though no difference was detected at baseline testing, motor block was significantly prolonged in diabetic as compared with control rats (137 ± 16 vs 86 ± 17 min).
In vitro, local anesthetic neurotoxicity was more pronounced on neurons from diabetic animals, but the survival difference was small. In vivo, subclinical neuropathy leads to substantial prolongation of block duration. We conclude that early diabetic neuropathy increases block duration, whereas the observed increase in toxicity was small.
应用局部麻醉剂可能导致神经损伤。越来越多的证据表明,糖尿病周围神经病变患者的神经毒性风险更高。此外,神经病变患者的阻滞时间可能会延长。我们试图在 2 型糖尿病的遗传动物模型中研究体外神经毒性和体内阻滞时间。
在第一项实验中,取自对照 Zucker 糖尿病肥胖(ZDF)大鼠的神经元暴露于急性(24 小时)或慢性(72 小时)高血糖,随后用 40mM 利多卡因(约 1%)孵育。在第二项实验中,取自对照 ZDF 大鼠或糖尿病 ZDF 大鼠的神经元用利多卡因孵育,或用 p38 丝裂原活化蛋白激酶抑制剂 SB203580 孵育。最后,我们在对照或糖尿病 ZDF 大鼠中进行坐骨神经阻滞(利多卡因 2%,0.2mL),并测量运动和感觉阻滞持续时间。
体外,急性或慢性高血糖均未改变利多卡因的神经毒性特性。体外,取自糖尿病(57%±19%)大鼠的神经元与利多卡因孵育后,与取自对照(64%±9%)大鼠的神经元相比,存活比例略有下降。添加 SB203580 部分逆转了这种增强的神经毒性作用,使糖尿病神经元的存活率提高至 71%±12%,对照大鼠的存活率提高至 66%±9%。体内,尽管在基线测试中未检测到差异,但与对照大鼠相比,运动阻滞在糖尿病大鼠中显著延长(137±16 比 86±17 分钟)。
体外,来自糖尿病动物的神经元的局部麻醉剂神经毒性更为明显,但存活差异较小。体内,亚临床神经病变导致阻滞时间显著延长。我们得出结论,早期糖尿病周围神经病变会延长阻滞时间,而观察到的毒性增加则较小。